FDA Flip-Flop: mRNA Flu Shot OK’d

The Food and Drug Administration just cleared the first flu shot ever built on mRNA technology, opening a new chapter for a vaccine platform that made its name during COVID-19.

Story Snapshot

The FDA approved Moderna’s mFLUSIVA on August 5, 2026, the first messenger RNA seasonal flu vaccine cleared in the United States.
Adults 50 to 64 get standard approval based on a full Phase 3 trial; adults 65 and older get accelerated approval, with a required follow-up study still to come.
An FDA advisory panel voted 9-0 in June that the shot’s benefits outweigh its risks for both age groups.
The approval follows a bumpy path, including an earlier FDA refusal to even review Moderna’s application.

A New Kind Of Flu Shot Reaches The Market

Moderna’s mFLUSIVA, known scientifically as mRNA-1010, will hit pharmacies for the 2026-2027 flu season. It targets adults 50 and older, a group that faces higher rates of flu-related hospitalization and death every year. In a trial covering people 50 to 64, the shot cut confirmed flu illness by 27 percent compared with a standard vaccine, according to Moderna’s own data.

That 27 percent number matters because traditional flu shots grow their virus particles in eggs or cells, a slow process that limits how quickly manufacturers can react to a fast-mutating strain. Messenger RNA shots skip that step. They teach the body to build its own copy of a viral protein, which supporters say could let drugmakers update formulas faster when a nasty new flu strain emerges.

The Regulator Said No Before It Said Yes

This approval almost didn’t happen. Back in February 2026, the FDA initially refused to even process Moderna’s application, a rare and startling move that rattled Wall Street and public health circles alike. Moderna pushed back, met with the agency, and reworked its regulatory strategy. The FDA reversed course and agreed to review the shot, setting up the advisory committee vote that followed four months later.

That committee, the Vaccines and Related Biological Products Advisory Committee, voted unanimously, 9 to 0, that the vaccine’s benefits outweigh its risks for both the 50-to-64 group and the 65-and-older group. Federal advisers found no new safety red flags during their review of the trial data.

Why Older Adults Got A Different Kind Of Approval

Here’s the detail that matters most for anyone over 65: the FDA split its decision. Adults 50 to 64 received full, traditional approval based on a completed randomized trial. Adults 65 and older received accelerated approval instead, a pathway the FDA uses when early evidence looks promising but the complete picture isn’t finished yet.

Accelerated approval comes with a condition. Moderna must run a follow-up study to confirm the vaccine actually works as well in older, often frailer patients as the early data suggests. This isn’t unusual in drug regulation, but it is a meaningful distinction. It means the strongest, most complete evidence right now applies to the younger half of the approved population, not the older half who may need the shot most.

Old Wounds Around mRNA Still Shape The Reaction

Public reaction has split along familiar lines. Some doctors and outlets have welcomed the shot as a scientific milestone, a sign that mRNA technology can move beyond COVID-19 into everyday preventive medicine. Others, including vocal critics online, have raised the same worries that trailed COVID mRNA vaccines: myocarditis risk, rushed timelines, and distrust of a regulator that reversed itself once already this year.

What’s not accurate:
The language about “increased risks of myocarditis and pericarditis… highest in males 12 through 24 years of age” is not in the mFLUSIVA (Moderna mRNA flu vaccine) fact sheet or prescribing information. That exact wording comes from the mRNA COVID-19 vaccine…

— Katt (@Katt3jc1) August 7, 2026

Both reactions have a point worth taking seriously. The unanimous advisory vote and clean safety review are real and shouldn’t be waved away. But the accelerated approval for seniors, paired with a mandatory follow-up study, is also real, and it means the evidence for the group that needs the most protection isn’t fully locked down yet. Skepticism about that gap isn’t fear-mongering, it’s just reading the label closely, something the FDA itself built into the approval terms.

What Comes Next For Patients And Doctors

Pharmacies and clinics expect to stock mFLUSIVA alongside traditional flu shots this fall, giving older adults a genuine choice for the first time. Whether it becomes the preferred option will likely hinge on how Moderna’s required senior study turns out and whether real-world results match the trial’s promising numbers. Until then, patients over 65 have a reasonable case for asking their doctor detailed questions before rolling up a sleeve.